信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 03-27 16:08:20

85.500

+6.100

+7.68%

最高86.050	最低79.850	成交量2,622万
今开80.100	昨收79.400	日振幅7.81%
总市值1,483亿	流通市值1,483亿	总股本17.35亿
成交额22.08亿	换手率1.51%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":85.5,"timestamp":1774598900002,"preClose":79.4,"halted":0,"volume":26224718,"delay":0,"changeRate":0.07682619647355156,"floatShares":1735000000,"shares":1735000000,"eps":-0.06,"marketStatus":"已收盘","change":6.1,"latestTime":"03-27 16:08:20","open":80.1,"high":86.05,"low":79.85,"amount":2208268743,"amplitude":0.078086,"askPrice":85.55,"askSize":3500,"bidPrice":85.5,"bidSize":76000,"shortable":3,"etf":0,"ttmEps":0.739283,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":79.4,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":2.644553,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5321,"impliedVolPercentile":0.3862},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2622846819","title":"花旗：升信达生物(01801)目标价至115港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846819","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622846819?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:50","pubTimestamp":1774597851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，信达生物去年收入同比升38%至130亿元人民币，纯利录得8.34亿元人民币，同比扭亏为盈。管理阶层重申2027年产品销售额为200亿元人民币指引。管理层指出，尽管近期价格调整和竞争加剧，但玛仕度肽销售仍保持良好势头。该行对公司今年和明年收入上调24%及23%，各年每股盈测分别上调33%及5%，其目标价由110港元上调至115港元，维持其评级为“买入”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01801"],"gpt_icon":0},{"id":"1184490371","title":"港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184490371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184490371?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:05","pubTimestamp":1774587950,"startTime":"0","endTime":"0","summary":"信达生物涨超7%，君实生物、诺诚健华涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","01801","09969","06127","01877"],"gpt_icon":0},{"id":"2622814147","title":"港股异动丨业绩亮眼，信达生物大涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814147","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814147?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:17","pubTimestamp":1774585022,"startTime":"0","endTime":"0","summary":"信达生物(1801.HK)盘中拉升涨超7%，报85.55港元。消息面上，公司昨晚公布业绩显示，2025年实现总收入130.415亿元，同比增38.4%；国际财务报告准则(IFRS)净利润8.136亿元，去年亏损9463万元，同比扭亏为盈，为公司首次全年盈利；Non-IFRS净利润17.231亿元，同比增419.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260327/32103895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2097828631.EUR","LU2488822045.USD","HK0000165453.HKD","BK1589","LU2097828714.EUR","LU1969619763.USD","LU0502904849.HKD","BK1583","LU2097828474.EUR","LU2097828557.USD","LU0455707207.USD","BK4588","LU2242644610.SGD","BK1161","01801","LU2097828805.USD","VXUS","BK4585","LU2328871848.SGD"],"gpt_icon":0},{"id":"2622581161","title":"5分钟，封死涨停！千亿巨头，彻底引爆！整个板块集体飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622581161","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622581161?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:31","pubTimestamp":1774582260,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　昨天是锂电池，今天轮到创新药。3月27日早盘，创新药概念持续走高，美诺华（维权）开盘后五分钟封死涨停板，科拓生物20CM涨停，万邦德、联环药业、双鹭药业涨停，热景生物、益诺思涨超10%。A股创新药板块大涨3%。　　港股方面亦有反应，信达生物首次全面盈利，重磅战略合作加速兑现管线全球价值，该股一度大涨超7%。彻底引爆整个生物医药板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-03-27/doc-inhskwcy5485109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828557.USD","LU2488822045.USD","HK0000165453.HKD","LU0455707207.USD","06978","BK1574","LU1969619763.USD","LU2097828474.EUR","LU2242644610.SGD","LU2097828805.USD","BK1589","LU2097828631.EUR","LU2328871848.SGD","BK1161","BK1583","01801","LU0502904849.HKD","LU2097828714.EUR"],"gpt_icon":0},{"id":"2622127088","title":"港股创新药集体飙升！信达生物首次全面盈利，一度涨超7%，机构：预期差依然存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2622127088","media":"券商中国","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622127088?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:31","pubTimestamp":1774582260,"startTime":"0","endTime":"0","summary":"今天轮到创新药！昨天是锂电池，今天轮到创新药。3月27日早盘，创新药概念持续走高，美诺华开盘后五分钟封死涨停板，科拓生物20CM涨停，万邦德、联环药业、双鹭药业涨停，热景生物、益诺思涨超10%。A股创新药板块大涨3%。港股方面亦有反应，信达生物首次全面盈利，重磅战略合作加速兑现管线全球价值，该股一度大涨超7%。彻底引爆整个生物医药板块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202603273686787813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["BK1161","LU2097828474.EUR","BK1589","06978","HK0000165453.HKD","01801","LU0455707207.USD","LU0502904849.HKD","BK4588","LU2488822045.USD","LU2097828805.USD","LU2328871848.SGD","LU2097828631.EUR","159992","LU2242644610.SGD","BK1574","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","BK4585","BK1583","VXUS"],"gpt_icon":0},{"id":"2622161038","title":"信达生物早盘涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622161038","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622161038?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:10","pubTimestamp":1774577424,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月27日，信达生物(01801.HK)早盘涨超5%，截至发稿，涨5.48%，报83.75港元，成交额4.74亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686706113.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686706113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","BK1161","LU2242644610.SGD","BK1589","HK0000165453.HKD","LU2328871848.SGD","LU0455707207.USD","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2097828805.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828557.USD","01801","LU2097828631.EUR"],"gpt_icon":0},{"id":"1179838817","title":"异动解读 | 信达生物2025年首次扭亏为盈，股价盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179838817","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179838817?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:57","pubTimestamp":1774576632,"startTime":"0","endTime":"0","summary":"信达生物今日盘中股价大涨5.04%，引起了市场的广泛关注。消息面上，公司发布的2025年年报显示，其全年实现总收入130.42亿元，同比增长38.4%；归母净利润达到8.14亿元，同比大幅增长959.72%，这是公司首次实现全年盈利。这一里程碑式的业绩突破，被市场视为公司发展史上的重要转折点，有效提振了投资者信心。分析指出，此次扭亏为盈打破了市场对创新药企业“高投入、低产出”的固有印象，成为创新药板块估值修复的重要催化剂。公司业绩在业务规模、盈利能力和全球化创新三个维度均实现了历史性突破，为股价上涨提供了坚实的基本面支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"gpt_icon":0},{"id":"2622289783","title":"信达生物2025年首次扭亏为盈；周云曙出任先声药业CEO | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289783","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622289783?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:00","pubTimestamp":1774566006,"startTime":"0","endTime":"0","summary":"丨2026年3月27日星期五丨NO.1京东健康宿迁天宁股权结构调整3月26日，京东健康宣布，为提高行政效率，李娅云于2026年3月26日订立股权转让协议，据此李娅云同意将其在宿迁天宁持有的30%股权转让予隋婷婷。由于一名登记股东变更，宿迁天宁、外商独资企业及新登记股东订立新合同安排，现有合同安排同时终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686096042.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686096042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","BK0012","LU1997245177.USD","BK0239","LU2580892789.USD","BK1191","LU1997245094.SGD","09939","LU2488822045.USD","LU2097828474.EUR","LU2289578879.USD","BK0196","LU2242644610.SGD","BK0060","LU1255011170.USD","LU0405327148.USD","LU1064131003.USD","LU0455707207.USD","BK0188","LU2097828631.EUR","BK1515","LU1580142542.USD","LU2097828714.EUR","LU2148510915.USD","LU1781817850.SGD","01801","BK0028","159938","LU0502904849.HKD","LU2580892862.HKD","BK0183","LU2097828805.USD","02096","LU2328871848.SGD","LU1997244956.HKD","LU1655091616.SGD","BK1583","LU0405327494.USD","600276","BK1161","LU1064130708.USD","BK1574","LU1328615791.USD","LU2097828557.USD","HK0000165453.HKD","LU1820825898.SGD","BK1589","LU1969619763.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2622855356","title":"信达生物(01801)发布2025年度业绩，净利润8.136亿元，实现首个完整年度盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855356","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622855356?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:53","pubTimestamp":1774518800,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布截至2025年12月31日止年度业绩，总收入130.415亿元，同比增长38.4%;自2019年首款产品上市以来，商业化规模快速扩张，充分反映出公司的前瞻性的战略布局和高效的商业化执行能力。公司实现了首个完整年度盈利。IFRS计量下净利润达到8.136亿元。截至2025年12月31日止年度及直至本公告日期，公司实现“双轮驱动”战略升级，肿瘤地位领先，综合产品线贡献新增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)发布2025年度业绩，净利润8.136亿元，实现首个完整年度盈利","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":1},{"id":"2622783622","title":"老百姓大药房与信达生物深化战略合作 携手共拓创新药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783622","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622783622?lang=zh_cn&edition=full","pubTime":"2026-03-26 14:24","pubTimestamp":1774506240,"startTime":"0","endTime":"0","summary":"本报讯受处方外流持续推进影响，对于部分进院难度较大的创新药，零售药房已成为实现商业化落地、提升患者可及性的重要渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685418646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0502904849.HKD","BK1161","BK1589","603883","LU2097828474.EUR","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","BK0209","159992","LU2242644610.SGD","01801","06978","BK1574","LU2097828714.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2622001480","title":"信达生物(01801)与礼来制药的战略合作已生效 澄清非收购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622001480?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:43","pubTimestamp":1774395814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域新药研发所作出的公告。公司已获联邦贸易委员会提前批准，至此，礼来制药与公司之间战略合作协议生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。公司注意到，部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清，公司并未，亦无意进行该等交易。谨此提醒股东及有意投资者，切勿依赖有关集团的市场传闻。有关集团的任何资讯，应仅以公司的官方公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"653eee3a804e75521c76cf05d37467c2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LLII","LU2112291526.USD","LU2491050154.USD","IE00BK4W5M84.HKD","LU1804176565.USD","LU0096364046.USD","SG9999013999.USD","LU2750360641.GBP","LU1814569148.SGD","LU0266013472.USD","LU0323591593.USD","LU1974910355.USD","LU0672654240.SGD","IE00BN29S564.USD","LU2168564222.USD","LU2237443549.SGD","LU2271345857.HKD","LU2237443382.USD","SG9999014906.USD","BK1574","SG9999015945.SGD","LU1983299246.USD","LU1551013425.SGD","BK4588","LU1969619763.USD","LU2491049909.HKD","LU2097828557.USD","LU2237443978.SGD","LU2552382058.USD","IE00B2B36J28.USD","LU1720051017.SGD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","LU1035775433.USD","IE00B4R5TH58.HKD","LU0097036916.USD","LU2237443465.HKD","LU2488822045.USD","LU2746668461.USD","LU0471298694.HKD","LU2237438978.USD","BK1191","SGXZ57979304.SGD","LU0256863902.USD","IE00B1BXHZ80.USD","LU2746668974.SGD","LU0203202063.USD","BK1583","LU0006306889.USD","LU2168564149.EUR","LU1868836757.USD","BK4534","LU0210536198.USD","SG9999018865.SGD","IE0004445239.USD","LU2089984988.USD","LU2750360997.AUD","LU0234572021.USD","LU1366192091.USD","LU2265009873.SGD","LU1064131342.USD","LU0683600562.USD","LU2324357040.USD","LU2168564065.EUR","LU2089283258.USD","LU1629891620.HKD","LU2023250330.USD","LU0455707207.USD","LU1232071149.USD","LU1720051108.HKD","LU2023250504.SGD","LU0820561909.HKD","LU2168564495.EUR","LU1868836914.USD","LU2461242641.AUD","SG9999014898.SGD","LU1127390331.HKD","LU1057294990.SGD","LU2328871848.SGD","LU0354030511.USD","LU0320765992.SGD","LU0353189763.USD","LU2106854487.HKD","LU2168563687.JPY","LU0708995401.HKD","LU0882574055.USD","IE00BKPKM429.USD","LU2087625088.SGD","LU2237443622.USD","LU0786609619.USD","LU1280957306.USD","LU0456855351.SGD","LU2089284900.SGD","LU0385154629.USD","IE00B1XK9C88.USD","LU0882574139.USD","LU2237443895.HKD","SGXZ31699556.SGD","LU2097828805.USD","LU2211815571.USD","IE00BK4W5L77.USD","LU0823416689.USD","LU2111349929.HKD","LU2468319806.SGD","LU0502904849.HKD","LU2456880835.USD","LU1868836591.USD","LU1548497426.USD","LU0689472784.USD","IE00BFSS8Q28.SGD","LU1989771016.USD","LU0058720904.USD","LU0158827781.USD","LU0787776722.HKD","LU0122379950.USD","LU2097828474.EUR","SG9999014914.USD","LU0256863811.USD","LU2471134523.USD","LU0820561818.USD","SG9999014880.SGD","BK4585","LU2063271972.USD","IE0002141913.USD","SGXZ51526630.SGD","LU0823434740.USD","SG9999001176.USD","LU1551013342.USD","LU1145028129.USD","LU2361044865.SGD","LU1061106388.HKD","LU2491050071.SGD","ELIL","LU2471134879.HKD","IE00BJJMRX11.SGD","LU0820562030.AUD","HK0000165453.HKD","LU1623119135.USD","LU1291159041.SGD","LU2361045086.USD","LU0943347566.SGD","LU0198837287.USD","LU2417539215.USD","BK1161","LU1917777945.USD","LU0471298777.SGD","LU2264538146.SGD","SG9999017495.SGD","LU0353189680.USD","LU2213496289.HKD","BK4533","IE00B775H168.HKD","IE00BJJMRZ35.SGD","LU2242644610.SGD","LU2552382215.SGD","01801","IE0009355771.USD","LU0158827948.USD","LU0417517546.SGD","LU0354030438.USD","LU0889565916.HKD","BK4516","IE00BFTCPJ56.SGD","LU0109394709.USD","IE0001KFT4U8.USD","LU0203201768.USD","LU1323610961.USD","LU1712237335.SGD","BK4599","IE00B7KXQ091.USD","LU0061475181.USD","LU2023251221.USD","SGXZ99366536.SGD","LLYZ","SG9999015986.USD","LU0964807845.USD","LU0320765059.SGD","LU0640476718.USD","LU1093756168.USD","SG9999001176.SGD","LU0432979614.USD","LU0114720955.EUR","BK4007","LU0289739699.SGD","LU2552382132.HKD","LU2108987350.USD","ELIS","IE00BJLML261.HKD","LU0109391861.USD","IE00BWXC8680.SGD","LU1093756325.SGD","SGXZ81514606.USD","SG9999015978.USD","BK1589","IE0004445015.USD","LU2602419157.SGD","LU2028103732.USD","LU0823434583.USD","LU0079474960.USD","LU0094547139.USD","LU0316494557.USD","LU2097828714.EUR","SG9999015952.SGD","LU0238689110.USD","LU2471134952.CNY","LU2360106947.USD","LU1868837136.USD","IE00BFSS7M15.SGD","LU1023059063.AUD","LU1069344957.HKD","LU2756315318.SGD","LU0466842654.USD","LU2357305700.SGD","LU2236285917.USD","IE0005OL40V9.USD","LU2097828631.EUR","LU1868837300.USD","LU1988902786.USD","LU2471134796.USD","BK4581","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","LLYX","LU1267930730.SGD","LU2361044949.HKD","LU2756315664.SGD","LU2896262040.SGD","IE00BKDWB100.SGD","SG9999018857.SGD","LU0225283273.USD","LU2462157665.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"1171306437","title":"信达生物与礼来战略合作协议生效先决条件已全部满足","url":"https://stock-news.laohu8.com/highlight/detail?id=1171306437","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171306437?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:02","pubTimestamp":1774393332,"startTime":"0","endTime":"0","summary":"信达生物与礼来公司达成的战略合作协议，其生效所需满足的全部先决条件现已完成。\n此举标志着双方在生物医药领域的合作迈入了全新的实质性阶段，为后续的深度协作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","BK1161","LU2097828714.EUR","BK1583","LU0455707207.USD","LU1969619763.USD","LU0502904849.HKD","01801","LU2328871848.SGD","BK1589","LU2242644610.SGD","LU2097828557.USD","LU2097828631.EUR","LU2488822045.USD","HK0000165453.HKD","LU2097828805.USD"],"gpt_icon":0},{"id":"2621069604","title":"摩根大通增持信达生物(01801)约49.78万股 每股作价约82.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069604","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621069604?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:02","pubTimestamp":1774350158,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月19日，摩根大通增持信达生物(01801)49.7823万股，每股作价82.2756港元，总金额约为4095.87万港元。增持后最新持股数目约为8724.97万股，持股比例为5.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"摩根大通增持信达生物(01801)约49.78万股 每股作价约82.28港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0455707207.USD","01801","JPMO","LU2237443622.USD","LU0943347566.SGD","LU1119994496.HKD","LU2097828557.USD","BK4566","LU1261432733.SGD","LU1496350502.SGD","IE00BLSP4452.SGD","LU0640476718.USD","LU2097828474.EUR","LU2328871848.SGD","BK1589","LU0208291251.USD","LU0345770993.USD","LU2430703251.USD","LU0265550359.USD","LU0683600562.USD","LU0265550946.USD","LU0964807845.USD","BK4585","LU0976567544.SGD","IE00B3S45H60.SGD","LU1244550221.USD","LU2097828805.USD","LU2211815571.USD","LU0070302665.USD","BK4207","BK1161","LU1551013425.SGD","LU0215105999.USD","IE00BJLML261.HKD","BK4581","LU0006306889.USD","IE000M9KFDE8.USD","LU0942090050.USD","LU1116320737.USD","LU2106854487.HKD","LU1280957306.USD","LU1988902786.USD","LU0345769128.USD","BK4588","LU1244550577.SGD","LU1670627923.USD","LU1064131342.USD","LU1496350171.SGD","IE00BWXC8680.SGD","LU0417517546.SGD"],"gpt_icon":0},{"id":"1150862394","title":"信达生物Efdamrofusp Alfa（IBI302）III期注册STAR研究达主要终点，成中国首个自主研发的NAMD长效疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1150862394","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150862394?lang=zh_cn&edition=full","pubTime":"2026-03-24 08:03","pubTimestamp":1774310593,"startTime":"0","endTime":"0","summary":"信达生物制药宣布，其自主研发的Efdamrofusp Alfa（研发代号：IBI302）用于治疗新生血管性年龄相关性黄斑变性（nAMD）的III期注册临床研究（STAR研究）已达到主要研究终点。该成果标志着IBI302有望成为中国首个本土研发的延长给药间隔的nAMD治疗药物，为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828631.EUR","LU2328871848.SGD","01801","BK1583","LU2097828474.EUR","BK1161","LU2097828805.USD","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU0502904849.HKD","BK1589","LU0455707207.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2620449806","title":"招银国际：料中国医疗行业基本面加速向好 推荐买信达生物(01801)三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449806?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:07","pubTimestamp":1773731228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨0.6%，跑赢MSCI中国指数3.5%。医药行业近期明显回调，特别是创新药板块回调幅度较大。同时，AI制药技术突破与中国创新药踏出海外BD的爆发形成双重共振，该行预计行业基本面加速向好。该行表示，推荐买入信达生物、三生制药、加科思、固生堂 、药明合联，目标价分别110.62港元、37.43港元、10.34港元、44.95港元及88港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d0f3c5bccb622a532fbc5668691928ff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1219","BK1141","BK1593","LU0455707207.USD","BK1583","01801","LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","LU1969619763.USD","02268","02273","LU2097828631.EUR","LU0502904849.HKD","LU2242644610.SGD","SG9999014674.SGD","159891","BK1161","BK1589","LU2097828474.EUR","BK1574","01167","LU2097828557.USD"],"gpt_icon":0},{"id":"2618925435","title":"医药生物行业周报：罗伐昔替尼达成高额独家授权协议，创新药BD交易持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618925435","media":"上海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618925435?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:05","pubTimestamp":1773209138,"startTime":"0","endTime":"0","summary":"主要观点2026年3月4日，中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议，中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。四起交易均为临床前资产，彰显中国源头创新能力获全球认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226288170.HKD","LU1226287875.USD","LU1226288253.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU1951186391.HKD","LU1993786604.SGD","LU1226287792.SGD","LU1813983027.USD","SG9999004220.SGD","BK1515","01801","IE00B543WZ88.USD","IE0008368742.USD","BK1574","LU1328277881.USD","LU0880133367.SGD","06978","LU1152091168.USD","BK1161","LU1152091754.HKD","LU0326950275.SGD","LU0501845795.SGD","01177","LU1008478684.HKD","LU0067412154.USD","HK0000165453.HKD","01093","LU0315179316.USD","LU1226287529.USD","BK1191","LU2039709279.SGD","IE00BZ08YR35.GBP","LU0072913022.USD","IE0008369823.USD","BK1521","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU0140636845.USD","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2618094075","title":"翰森制药、恒瑞医药等齐发力，国产GLP-1类减重药加速“破圈”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094075","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618094075?lang=zh_cn&edition=full","pubTime":"2026-03-11 11:32","pubTimestamp":1773199961,"startTime":"0","endTime":"0","summary":"据悉，在减重药物领域，GLP-1类药物成为热门赛道，国内一批药企也积极抢占这一赛道，并逐渐迎来收获。除了翰森制药外，还有一批国产GLP-1类新药正在加速推进临床。值得一提的是，目前已有多个国产GLP-1类新药获批上市。从临床推进到上市落地，国产GLP-1类药物的多点突破，彰显了我国生物医药产业的自主创新实力。未来，随着药企持续加大研发投入，聚焦剂型创新、适应症拓展，国产GLP-1类药物将在全球肥胖防控领域发挥更重要的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","BK1191","01801","LU0359202008.SGD","LU2543165471.USD","03692","BK1589","01276","BK1583","LU0359201612.USD"],"gpt_icon":0},{"id":"2618629569","title":"每日卖空追踪 | 信达生物 03月10日卖空量成交156.45万股，卖空比例为12.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629569","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618629569?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131425,"startTime":"0","endTime":"0","summary":"信达生物北京时间03月10日，涨4.95%，卖空量成交156.45万股，较上一交易日减少63.74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163303a45df73a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163303a45df73a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0455707207.USD","LU2242644610.SGD","LU2097828805.USD","BK1583","LU2328871848.SGD","BK1161","01801","HK0000165453.HKD","LU0502904849.HKD","BK1589","LU2097828474.EUR","LU2097828631.EUR","LU2488822045.USD","LU2097828714.EUR","LU1969619763.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2618896295","title":"信达生物03月10日主力净流入3770.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618896295","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618896295?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:16","pubTimestamp":1773130560,"startTime":"0","endTime":"0","summary":"03月10日, 信达生物股价涨4.95%，报收85.80元，成交金额10.9亿元，换手率0.73%，振幅3.30%，量比0.89。信达生物今日主力资金净流入3770.6万元，上一交易日主力净流出3281.8万元。该股近5个交易日上涨8.00%，主力资金累计净流入2996.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3.6亿元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310162128a45dec7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310162128a45dec7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2097828805.USD","LU0455707207.USD","LU2097828714.EUR","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","BK1583","BK1161","LU2097828474.EUR","LU2488822045.USD","LU2328871848.SGD","HK0000165453.HKD","LU2097828557.USD","01801","BK1589"],"gpt_icon":0},{"id":"2618360608","title":"信达生物IBI3033启动一期临床 适应症为哮喘、特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360608","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618360608?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:03","pubTimestamp":1773050580,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的IBI3033在健康受试者中安全性、耐受性及药代动力学的随机、双盲、安慰剂对照的多次给药研究已启动。本次试验主要目的为评估健康受试者接受IBI3033多次给药后的安全性和耐受性。IBI3033为生物制品，适应症为哮喘、特应性皮炎。哮喘是气道慢性炎症性疾病，表现为喘息、气促等；特应性皮炎是慢性复发性炎症性皮肤病，以剧烈瘙痒和湿疹样皮疹为特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030919044097ab0b06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030919044097ab0b06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","HK0000165453.HKD","LU2488822045.USD","01801","LU1969619763.USD","LU2097828805.USD","LU2242644610.SGD","BK1589","BK1161","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","LU2097828631.EUR","LU2097828714.EUR","LU2328871848.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0299},{"period":"1month","weight":-0.1033},{"period":"3month","weight":-0.0167},{"period":"6month","weight":-0.1485},{"period":"1year","weight":1.0333},{"period":"ytd","weight":0.0413}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0652},{"period":"3month","weight":-0.0373},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0585},{"period":"ytd","weight":-0.0302}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.027419},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}